文献速递血栓与止血淋巴瘤

淋巴瘤患者静脉血栓并发症的治疗与预防

How I treat and prevent venous thrombotic complications in patients with lymphoma.
PubMed 文献 · Blood · 2022-01-01

淋巴瘤患者静脉血栓栓塞(VTE)发生率为5%至10%,随着新型疗法增加,VTE管理更复杂。治疗选择从华法林和低分子肝素扩展到直接口服抗凝药(DOACs)阿哌沙班、依度沙班和利伐沙班。无头对头试验比较不同DOACs,随机试验设计及结果存在差异。药物相互作用、药物特异性副作用和患者选择是抗凝治疗的重要考虑因素。

要点

  • 淋巴瘤患者VTE发生率为5%至10%。
  • DOACs(阿哌沙班、依度沙班、利伐沙班)可用于癌症相关VTE治疗。
  • 选择抗凝药需权衡血栓与出血风险、药物可及性及患者预期寿命。

核心结论

  • 淋巴瘤患者VTE常见,抗凝治疗选择需个体化,综合考虑血栓和出血风险、药物可及性及患者预期寿命。

主要发现

  • 淋巴瘤患者VTE发生率为5%至10%。
  • 治疗癌症相关VTE的选择包括华法林、低分子肝素(LMWHs)以及DOACs(阿哌沙班、依度沙班、利伐沙班)。
  • 尚无头对头试验比较不同DOACs,随机试验比较DOAC与LMWH达肝素的设计和结果存在差异。

临床怎么用

  • 处方抗凝治疗时应考虑药物相互作用、药物特异性副作用和患者选择。
  • 所有患者需评估血栓和出血的相对风险、抗凝药可及性及预期寿命,以选择最合适的抗凝药(可随时间变化)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism (VTE) is a common complication occurring in 5% to 10% of patients with lymphoma. As the complexity of lymphoma management has increased with novel therapies, so too has the treatment of VTE. Therapeutic options for the treatment of cancer-associated VTE have expanded from only warfarin and low-molecular-weight heparins (LMWHs) to include the direct oral anticoagulants (DOACs) apixaban, edoxaban and rivaroxaban. There have been no head-to-head trials comparing different DOACs in this setting, and randomized trials comparing a DOAC with LMWH dalteparin differ in trial design and results. Drug-drug interactions, drug-specific side effects, and patient selection are important considerations when prescribing anticoagulant therapy. In all patients, the relative risks of thrombosis and bleeding, the availability of the anticoagulant, and the life expectancy of the patient are vital elements in selecting the most appropriate anticoagulant (which can vary over time) for the individual patient. We describe the intricacies and challenges of treating thrombotic complications in patients with lymphoma with an emphasis on evidence and guideline-based care.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Schmidt RA, Lee AYY. How I treat and prevent venous thrombotic complications in patients with lymphoma. Blood. 2022. PMID: 34479364. doi:10.1182/blood.2019003689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。